Join our daily newsletter At The Bell to receive exclusive market insights
- Biotech company Immutep (IMM) enrols its last patient in its trial on non-small cell lung cancer patients
- 154 patients are participating in the study across 19 clinical sites in Australia, Europe, the UK and US
- The trial will evaluate the combination of Immutep’s lead drug candidate, Efti with Merck & Co’s (MSD) KEYTRUDA in patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer
- Immutep says it expects to report further data from the trial at a scientific conference by early 2022
- Immutep shares are up 6.60 per cent, trading at 56.5 cents at 3:43 pm AEST
Biotech company Immutep (IMM) has enrolled its last patient in its current lung cancer trial.
Recruitment is now complete for Stage 2 of Part B of Immutep’s Phase II TACTI-002 study on second line refractory non-small cell lung cancer patients.
A total of 154 patients are now participating in the trial across 19 clinical sites in Australia, Europe, the UK and US, with recruitment continuing for the expansion stage of Part A.
The study is evaluating the combination of Immutep’s lead drug candidate, efti, with Merck & Co’s (MSD) KEYTRUDA in patients with second line head and neck squamous cell carcinoma, or non-small cell lung cancer in first and second line.
Immutep says data previously presented at the Society for Immunotherapy of Cancer 35th Anniversary 2020 Annual Meeting as part of a late breaker poster looked encouraging, especially when compared to alternative treatment options.
Immutep says it expects to report further data from the trial at a scientific conference by early 2022.
Immutep shares are up 6.60 per cent, trading at 56.5 cents at 3:43 pm AEST.
